Leadership Overview
Dexcel Pharma has 5 executives leading key functions including strategy, finance, information technology, and medical affairs.
Driven by a commitment to health, Dexcel Pharma develops, manufactures, and commercializes value-added branded prescription drugs, generics, and OTC products, supplying over 175 dosage forms to global markets and solidifying its position as Israel's largest privately owned pharmaceutical company.
Driven by a commitment to health, Dexcel Pharma develops, manufactures, and commercializes value-added branded prescription drugs, generics, and OTC products, supplying over 175 dosage forms to global markets and solidifying its position as Israel's largest privately owned pharmaceutical company.
Leadership Roles at Dexcel Pharma
Ufuoma Ezekiel - Chief Executive Officer
Ufuoma Ezekiel, the Chief Executive Officer at Dexcel Pharma, directs the overarching corporate strategy and operational execution for Israel's largest privately owned pharmaceutical company. This leadership role involves guiding the development, manufacturing, and commercialization of a diverse portfolio, encompassing branded prescription drugs, generics, and over-the-counter products. Ezekiel's focus centers on optimizing the company's market presence across key regions, including the U.S., U.K., and Germany, through strategic expansion and robust distribution networks. The Chief Executive Officer ensures alignment with the company's mission to deliver high-quality pharmaceutical solutions. Ufuoma Ezekiel drives initiatives that enhance Dexcel Pharma's competitive edge in the global pharmaceutical landscape, emphasizing innovation and market responsiveness in all strategic decisions.
Ilan Oren - Co-Chief Executive Officer
Ilan Oren, the Co-Chief Executive Officer at Dexcel Pharma, shares executive leadership responsibilities, focusing on strategic growth and operational excellence. Oren collaborates to steer the company's development, manufacturing, and commercialization efforts for its extensive range of pharmaceutical products, including generics and OTC items. This role involves overseeing market penetration in critical territories such as the U.S. and Europe, leveraging Dexcel Pharma's established subsidiaries and distribution channels. The Co-Chief Executive Officer ensures that the company's value-added branded prescription drugs meet stringent quality standards and market demands. Ilan Oren contributes significantly to Dexcel Pharma's sustained expansion and its reputation as a leading pharmaceutical entity, driving forward the company's commitment to accessible healthcare solutions.
Yaron Erez - Chief Financial Officer & Vice President
Yaron Erez, the Chief Financial Officer & Vice President at Dexcel Pharma, manages all financial operations and fiscal strategy for the organization. Erez oversees budgeting, financial planning, and investment analysis, ensuring the fiscal health and sustainable growth of Israel's largest privately owned pharmaceutical company. This leadership position involves managing capital allocation for product development, manufacturing enhancements, and global market expansion across the U.S., U.K., and Germany. The Chief Financial Officer & Vice President also plays a crucial role in securing funding and optimizing financial performance to support the commercialization of generics and OTC products. Yaron Erez directs financial reporting and compliance, safeguarding Dexcel Pharma's assets and maximizing shareholder value through astute financial management.
Miri Peleg - Chief Information Officer & Vice President
Miri Peleg, the Chief Information Officer & Vice President at Dexcel Pharma, directs the company's information technology strategy and infrastructure. Peleg oversees the implementation and management of digital systems that support Dexcel Pharma's extensive operations, from research and development to manufacturing and global distribution. This critical role ensures the security, efficiency, and scalability of IT resources, facilitating the seamless commercialization of branded prescription drugs, generics, and OTC products across international markets. The Chief Information Officer & Vice President champions technological innovation to enhance operational workflows and data management. Miri Peleg drives digital transformation initiatives, ensuring Dexcel Pharma maintains a competitive advantage through robust and advanced technological capabilities.
Esther Hagai - Chief Medical Officer
Esther Hagai, the Chief Medical Officer at Dexcel Pharma, leads the company's medical affairs and clinical strategy. Hagai oversees the evaluation and development of pharmaceutical products, ensuring adherence to rigorous medical and regulatory standards across all therapeutic areas. This executive position involves guiding clinical research, post-market surveillance, and medical communication to support the efficacy and safety of Dexcel Pharma's branded prescription drugs, generics, and OTC offerings. The Chief Medical Officer plays a vital role in shaping the medical direction for product commercialization in key markets like the U.S. and Europe. Esther Hagai ensures that Dexcel Pharma's medical initiatives align with global healthcare needs and scientific advancements, reinforcing the company's commitment to patient well-being.
Explore Leadership Teams in Manufacturing
Founded in 1885, Boehringer Ingelheim is a pharmaceutical company which concentrates on the development of human pharmaceuticals, biopharmaceuticals, chemicals, and animal health products.
Company Leadership EM
RP
YL
Cambrex is a leading global contract development and manufacturing organization (CDMO) that provides drug substance, drug product, and analytical services across the entire drug lifecycle. With over 40 years of experience and a growing team of experts servicing global clients from North America and Europe, Cambrex is a trusted partner in branded and generic markets for API and finished dosage form development and manufacturing. Cambrex offers a range of specialized drug substance technologies and capabilities, including continuous flow, controlled substances, solid-state science, material characterization, stability storage, and highly potent APIs. In addition, Cambrex can support conventional dosage forms, including oral solids, semi-solids, and liquids, and has the expertise to manufacture specialty dosage forms such as modified-release, fixed-dose combination, pediatric, bi-layer tablets, stick packs, topicals, controlled substances, sterile, and non-sterile ointments.
Company Leadership
RG
MULPHICO (Multan Pharma International Co.) is a pharmaceutical manufacturing company based in Multan, Pakistan. Established in 1988, MULPHICO produces a wide range of generic medicines and healthcare products for domestic and international markets.
Company Leadership KN
IJ
MA
NK
Biophore specializes in the development and manufacturing of niche pharmaceutical products, focusing on APIs and intermediates for the global pharmaceutical industry. The company aims to enable its clients to reach the market quickly, ensuring faster access to patients. With a diverse product range and expertise in complex chemistry, Biophore is a trusted partner for collaborative projects. Their operations are supported by US FDA and EU approved manufacturing facilities, emphasizing quality and innovation.
Company Leadership KK
SA
RL
Frequently Asked Questions Regarding Dexcel Pharma Top Executives and Leadership Team
